|
US7723296B2
(en)
|
2001-01-18 |
2010-05-25 |
Genzyme Corporation |
Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
WO2003057179A2
(en)
|
2002-01-11 |
2003-07-17 |
Biomarin Pharmaceutical, Inc. |
Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
|
JP5589165B2
(ja)
|
2003-01-31 |
2014-09-17 |
マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー |
タンパク質欠損性障害の治療のための併用療法
|
|
JP5137814B2
(ja)
|
2005-04-06 |
2013-02-06 |
ジェンザイム・コーポレーション |
治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
|
|
EP3782655A1
(en)
|
2005-05-17 |
2021-02-24 |
Amicus Therapeutics, Inc. |
A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
|
|
CN102978185B
(zh)
|
2007-01-18 |
2015-02-11 |
建新公司 |
包含氨基氧基基团的寡糖及其轭合物
|
|
US8742079B2
(en)
|
2007-08-20 |
2014-06-03 |
Protalix Ltd. |
Saccharide-containing protein conjugates and uses thereof
|
|
PL3219795T3
(pl)
*
|
2008-01-18 |
2024-09-16 |
Biomarin Pharmaceutical Inc. |
Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
|
|
US7722865B2
(en)
|
2008-01-18 |
2010-05-25 |
Biomarin Pharmaceutical Inc. |
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
|
|
WO2009131698A2
(en)
*
|
2008-04-23 |
2009-10-29 |
Iowa State University Research Foundation, Inc. |
PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
|
|
WO2010056746A1
(en)
*
|
2008-11-11 |
2010-05-20 |
Amicus Therapeutics, Inc. |
Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
|
|
EP3608330B1
(en)
|
2008-12-16 |
2022-11-09 |
Genzyme Corporation |
Synthetic intermediates for preparing oligosaccharide-protein conjugates
|
|
ES2919563T3
(es)
*
|
2009-02-20 |
2022-07-27 |
Enhanx Biopharm Inc |
Sistema de administración de medicamentos a base de glutatión
|
|
CA2757645C
(en)
*
|
2009-04-06 |
2018-05-15 |
Mayo Foundation For Medical Education And Research |
Methods and materials for delivering molecules
|
|
US8785168B2
(en)
|
2009-06-17 |
2014-07-22 |
Biomarin Pharmaceutical Inc. |
Formulations for lysosomal enzymes
|
|
US9194011B2
(en)
|
2009-11-17 |
2015-11-24 |
Protalix Ltd. |
Stabilized alpha-galactosidase and uses thereof
|
|
CA2790786C
(en)
*
|
2010-02-24 |
2019-09-24 |
Zymenex A/S |
Process for production and purification of recombinant lysosomal alpha-mannosidase
|
|
WO2011108451A1
(ja)
*
|
2010-03-01 |
2011-09-09 |
日本ケミカルリサーチ株式会社 |
遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
|
|
JP6073783B2
(ja)
|
2010-06-25 |
2017-02-01 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
ヘパランn−スルファターゼのcns送達のための方法および組成物
|
|
CA2803166C
(en)
|
2010-06-25 |
2023-03-07 |
Shire Human Genetic Therapies, Inc. |
Cns delivery of therapeutic agents
|
|
BR112012033214B1
(pt)
|
2010-06-25 |
2020-11-03 |
Shire Human Genetic Therapies, Inc. |
uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente
|
|
EP2588132A4
(en)
*
|
2010-06-25 |
2014-10-15 |
Shire Human Genetic Therapies |
METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS
|
|
JP6045493B2
(ja)
|
2010-06-25 |
2016-12-14 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
アリールスルファターゼaのcns送達の方法および組成物
|
|
KR20130043165A
(ko)
|
2010-06-25 |
2013-04-29 |
샤이어 휴먼 지네틱 테라피즈 인크. |
이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
|
|
US8956859B1
(en)
|
2010-08-13 |
2015-02-17 |
Aviex Technologies Llc |
Compositions and methods for determining successful immunization by one or more vaccines
|
|
EP2665814B1
(en)
|
2011-01-20 |
2017-05-17 |
Protalix Ltd. |
Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
|
|
US9138465B2
(en)
|
2011-04-28 |
2015-09-22 |
Osaka University |
Pharmaceutical composition for treating lysosomal storage disease
|
|
WO2012157136A1
(ja)
*
|
2011-05-19 |
2012-11-22 |
財団法人東京都医学総合研究所 |
リン酸化糖鎖を含有する組換えヒトサポシンbタンパク質及びその用途
|
|
TW201307563A
(zh)
*
|
2011-05-19 |
2013-02-16 |
Shire Human Genetic Therapies |
純化乙醯肝素-n-硫酸酯酶之方法
|
|
US9387236B2
(en)
*
|
2011-06-10 |
2016-07-12 |
Prothera Inc. |
Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
|
|
AU2012278944B2
(en)
|
2011-07-05 |
2015-09-17 |
Bioasis Technologies Inc. |
p97-antibody conjugates and methods of use
|
|
CA2842492A1
(en)
|
2011-08-05 |
2013-02-14 |
Bioasis Technologies, Inc. |
P97 fragments with transfer activity
|
|
US20140377244A1
(en)
|
2011-12-23 |
2014-12-25 |
Shire Human Genetic Therapies, Inc. |
Stable formulations for cns delivery of arylsulfatase a
|
|
KR20200032244A
(ko)
|
2012-03-07 |
2020-03-25 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
|
|
RS61598B1
(sr)
|
2012-05-03 |
2021-04-29 |
Amicus Therapeutics Inc |
Režimi doziranja za tretman pompeove bolesti
|
|
WO2014022515A1
(en)
|
2012-07-31 |
2014-02-06 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
|
AU2013355046A1
(en)
*
|
2012-12-07 |
2015-05-14 |
Shire Human Genetic Therapies, Inc. |
Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis Type IIIA
|
|
NZ711373A
(en)
|
2013-03-13 |
2020-07-31 |
Bioasis Technologies Inc |
Fragments of p97 and uses thereof
|
|
JP6603227B2
(ja)
|
2014-02-03 |
2019-11-06 |
バイオアシス テクノロジーズ インコーポレイテッド |
P97融合タンパク質
|
|
AU2015219339B2
(en)
|
2014-02-19 |
2020-03-05 |
Bioasis Technologies Inc. |
P97-IDS fusion proteins
|
|
CA2943890A1
(en)
|
2014-05-01 |
2015-11-05 |
Bioasis Technologies, Inc. |
P97-polynucleotide conjugates
|
|
JP6851964B2
(ja)
|
2014-09-30 |
2021-03-31 |
アミカス セラピューティックス インコーポレイテッド |
炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
IL299470B2
(en)
*
|
2015-12-30 |
2026-05-01 |
Amicus Therapeutics Inc |
Improved acid alpha-glucosidase for the treatment of Pompe disease
|
|
CA3019354A1
(en)
|
2016-03-30 |
2017-10-05 |
Amicus Therapeutics, Inc. |
Method for selection of high m6p recombinant proteins
|
|
EP4793349A2
(en)
*
|
2016-03-30 |
2026-08-19 |
Amicus Therapeutics, Inc. |
Method for selection of high m6p recombinant proteins
|
|
KR102618519B1
(ko)
|
2016-03-30 |
2023-12-28 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
재조합 산 알파-글루코시다제를 포함하는 제형
|
|
EA039750B1
(ru)
*
|
2017-03-30 |
2022-03-10 |
Амикус Терапьютикс, Инк. |
Способ отбора рекомбинантных белков с высоким содержанием m6p
|
|
CN119113091A
(zh)
|
2017-05-15 |
2024-12-13 |
阿米库斯治疗学公司 |
重组人类酸性α-葡萄糖苷酶
|
|
AU2018281280B2
(en)
|
2017-06-07 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
|
CN112040985A
(zh)
|
2018-02-07 |
2020-12-04 |
瑞泽恩制药公司 |
用于递送治疗性蛋白质的方法和组合物
|
|
EP3793591A1
(en)
|
2018-05-17 |
2021-03-24 |
Regeneron Pharmaceuticals, Inc. |
Anti-cd63 antibodies, conjugates, and uses thereof
|
|
MX2022007399A
(es)
|
2019-12-20 |
2022-09-19 |
Codexis Inc |
Variantes de alfa-glucosidasa ácida diseñadas.
|
|
JP2026522950A
(ja)
*
|
2023-06-30 |
2026-07-09 |
クロスウォーク セラピューティクス, インコーポレイテッド |
操作された酸アルファ-グルコシダーゼバリアント
|